dr. h.c. Cees Smit, Long-term user of plasma products European Parliament, Brussels, January 22, 2019
MEDICAL PROGRESS IN HEMOPHILIA 1965 2015 2015
Life expectancy (years) Life expectancy (years) Life expectancy (years) Life expectancy (years) Life expectancy (years) 3 1975 1975 1975 1975 1975 40 40 40 40 40 50 50 50 50 50 60 60 60 60 60 70 70 70 70 70 80 80 80 80 80 90 90 90 90 90 1985 1985 1985 1985 1985 Time period Time period Time period Time period Time period 1995 1995 1995 1995 1995 2005 2005 2005 2005 2005 2015 2015 2015 2015 2015 Mild hemophilia Moderate hemophilia Severe hemophilia Dutch males All patients
CHALLENGES Dependency from just one country can be dangerous (hiv, bse) How to manage in the EU availability of essential medicines (def. WHO), like IVIG at the moment in Romania, Scotland and the UK Blood and plasma as ‘ strategic resources’ where EU should invest in ( ↑ international tensions ) Independent user groups of blood and plasma should be established Legal issues (no fault-compensation)
Recommend
More recommend